BMC Nephrology (Nov 2023)

Immune thrombocytopenia secondary to primary cytomegalovirus infection after renal transplantation treated with a thrombopoietin receptor agonist: a case report

  • Tomohiro Takehara,
  • Hayato Nishida,
  • Kazunobu Ichikawa,
  • Yuka Hosokawa,
  • Takaaki Nawano,
  • Satoshi Takai,
  • Hiroki Fukuhara,
  • Masahito Himuro,
  • Norihiko Tsuchiya,
  • Masafumi Watanabe

DOI
https://doi.org/10.1186/s12882-023-03385-x
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Immune thrombocytopenia (ITP) is an acquired disorder characterised by a low platelet count due to immune-mediated destruction and impaired platelet production. Here we report a rare case of primary cytomegalovirus (CMV) infection followed by thrombocytopenia after renal transplantation (RT). Case presentation A 24-year-old male patient with end-stage kidney disease secondary to hereditary focal segmental glomerulosclerosis was treated with peritoneal dialysis and received ABO-compatible living-related RT from his aunt. Nine months after the RT, the patient was diagnosed with primary CMV infection. After initiating treatment for primary CMV infection, the patient developed thrombocytopenia. After excluding other diseases or drugs that may cause thrombocytopenia, the patient was finally diagnosed with ITP, administered prednisolone (PSL), and started on Helicobacter pylori eradication therapy. Tapering the PSL dose was difficult, but thrombopoietin receptor agonists (TPO-RAs) were effective. Conclusions In this case, the patient was diagnosed with ITP, and other causes of thrombocytopenia after RT were successfully ruled out. This case report demonstrates that RT recipients can develop ITP after CMV infection, and, in such cases, TPO-RAs may be an attractive option as a second-line therapy.

Keywords